NCT04940871

Study to Assess the Efficacy and Safety of Favipiravir-HU

A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Favipiravir-HU Compared to Placebo as add-on Therapy to Standard of Care in Asymptomatic to Mild Severity COVID-19 Patients

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: University of Pecs · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The aim of the study is to assess the safety and efficacy of Favipiravir HU when administered to SARS-Cov- 2 patients in order to offer a safe and effective treatment to SARS-Cov-2 infection during the pandemic. The study is not for registration purposes and is not part of a series of studies for registration of Favipiravir HU.

Conditions

• Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Interventions

Type	Name	Description
DRUG	Favipiravir HU 200 mg hard capsules	Drug substance: Favipiravir Dose: 200 mg Administration: oral Formulation: capsules
DRUG	Placebo HU	Name: Placebo clinical sample Drug substance: placebo Dose: - Administration: oral Formulation: capsules

Timeline

• Start date: 2021-11-25
• Primary completion: 2021-11-29
• Completion: 2021-11-29
• First posted: 2021-06-28
• Last updated: 2022-11-09

Locations

1 site across 1 country: Hungary